arwatch.co.uk Report : Visit Site

Technical data of the arwatch.co.uk

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host arwatch.co.uk. Currently, hosted in Germany and its service provider is 1&1 Internet AG .

the related websites

ourwatch.org.uk www8.garmin.com ecglibrary.com nutraingredients-usa.com practicingmedicinewithoutalicense.com comparethemarket.com slimmingworld.com dailymail.co.uk skyros.com amazon.co.uk literature.org 

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called Apache containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

please login or register to print this page. a bjc resource for cardiac rhythm management arwatch innovations in cardiorenal medicine enhanced understanding of organ fibrosis and novel therapeutic targets were the focus of many presentations at last year’s 11th annual scientific meeting of the cardiorenal forum, held at the royal college of obstetricians and gynaecologists, london, on 6th october 2016. dr richard crawley reports on its highlights. in this issue atrial fibrillation and ckd chronic kidney disease (ckd), however we measure it, “signifies poor outcomes in atrial fibrillation patients”. this was a key message from dr ami banerjee (university college london). drawing on recent european society of cardiology guidelines, 1 he outlined how atrial fibrillation (af) is present in 15–20% of ckd patients (10–20 times higher than the general population). these patients have an increased stroke rate, and there is also a higher risk of bleeding in ckd. the big question in terms of non-valvular af and kidney disease is: how are they related? targeting uric acid the conference’s keynote lecture, delivered by professor austin stack (university hospital, limerick, ireland), homed in on the idea that serum uric acid directly contributes to increased cardiovascular disease. this was shown in his team’s work published in 2013, 1 which used retrospective data to identify a direct correlation between raised serum uric acid concentrations and increased risk of developing cardiovascular disease. sglt-2 inhibitors: a game changer? the results of the long awaited empa-reg (empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes) trial were discussed by dr amar puttanna (young diabetologists and endocrinologists forum, and west midlands deanery), then later mentioned in both the cardiology and renal trials updates, by professor john cleland (imperial college, london) and dr patrick mark (queen elizabeth university hospital, glasgow), respectively. novel functional imaging techniques an interesting talk regarding new imaging techniques based around magnetic resonance (mr), was led by dr aghogho odudu (university of manchester). the use of mr in cardiac and renal imaging is clearly growing, and the use of gadolinium to enhance both blood and extracellular fluid is a testament to the effectiveness of functional mr imaging. view our article archives current news acknowledgment february 21, 2017 -- the cardiorenal forum would like to thank the following companies for their generous support of the 2016 meeting: a menarini farmaceutica internazionale s.r.l., bristol-myers squibb, msd, novartis, pfizer, pharmacosmos, sanofi, servier, shire, ucb, vifor fresenius medical care renal pharma. slowing fibrosis february 21, 2017 -- professor tim johnson (university of sheffield, and ucb new medicines) discussed the implication of fibrosis (see table 1 ) in organ scarring in the western world, indicating that it is involved in 45% of all organ death. our targeting for future therapeutics, however, hasn’t been particularly successful of yet. the pcsk9 inhibitor phenomenon february 21, 2017 -- the work of professor jennifer robinson (university of iowa, usa) and her colleagues as part of the odyssey trial has been pivotal in demonstrating the effectiveness of the pcsk9 inhibitor, alirocumab. her lecture was timely given the recent national institute of health and care excellence (nice) recommendations (ta393) regarding the use of alirocumab in primary hypercholesterolaemia and mixed dyslipidaemia. 1 iv iron in heart failure february 21, 2017 -- the final lecture of the day, given by professor philip kalra (university of manchester), helped to elaborate on one of the hot topics in heart failure – the ongoing ironman study. anticoagulation achievement awards february 21, 2017 -- anticoagulation europe will this year host the first anticoagulation achievement awards – applications are welcome from outstanding clinical teams and individuals who provide exemplary care for any patient who has been diagnosed with atrial fibrillation or a blood clot such as deep vein thrombosis or a pulmonary embolism. diary date: crf 2017 february 21, 2017 -- make sure you save the date for our 2017 cardiorenal forum annual scientific meeting. last year’s meeting was extremely popular, with very positive feedback. full details of the programme and details of how you can register will be available soon at http://www.cardiorenalforum.com diary date: hrc 2017 february 21, 2017 -- more on the latest developments in electrophysiology, device management, syncope and healthcare delivery will be featured at next year’s heart rhythm congress, which will take place at the icc, birmingham, from 1st-4th october 2017. view our news archives members area log in or register now . search the site rss feed subscribe to our rss feed get exclusive updates sign up for our regular email newsletters & be the first to know about fresh articles and site updates. recent comments none found past issues february 2017 november 2016 october 2016 january 2016 november 2015 october 2015 september 2015 july 2015 june 2015 may 2015 april 2015 march 2015 endorsed by copyright © disclaimer home articles news about contact created by london design agency you are not logged in you need to be a member to print this page. sign up for free membership , or log in . you are not logged in you need to be a member to download pdf's. sign up for free membership , or log in .

URL analysis for arwatch.co.uk

http://arwatch.co.uk/
http://arwatch.co.uk/2017/02/anticoagulation-achievement-awards/
http://arwatch.co.uk/2017/02/targeting-uric-acid/
http://arwatch.co.uk/articles/
http://arwatch.co.uk/category/featured/
http://arwatch.co.uk/2017/02/atrial-fibrillation-and-ckd/
http://arwatch.co.uk/2015/09/
http://arwatch.co.uk/wp-login.php
http://arwatch.co.uk/category/news-and-views/
http://arwatch.co.uk/contact/
http://arwatch.co.uk/2016/10/
http://arwatch.co.uk/2017/02/sglt-2-inhibitors-a-game-changer/
http://arwatch.co.uk/2017/02/slowing-fibrosis/
http://arwatch.co.uk/2015/03/
http://arwatch.co.uk/2017/02/iv-iron-in-heart-failure/
bjcardio.co.uk
heartrhythmcharity.org.uk
atrialfibrillation.org.uk
consultantsindesign.co.uk
stars.org.uk

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Error for "arwatch.co.uk".

the WHOIS query quota for 2600:3c03:0000:0000:f03c:91ff:feae:779d has been exceeded
and will be replenished in 851 seconds

WHOIS lookup made at 03:03:16 31-Aug-2017

--
This WHOIS information is provided for free by Nominet UK the central registry
for .uk domain names. This information and the .uk WHOIS are:

Copyright Nominet UK 1996 - 2017.

You may not access the .uk WHOIS or use any data from it except as permitted
by the terms of use available in full at http://www.nominet.uk/whoisterms,
which includes restrictions on: (A) use of the data for advertising, or its
repackaging, recompilation, redistribution or reuse (B) obscuring, removing
or hiding any or all of this notice and (C) exceeding query rate or volume
limits. The data is provided on an 'as-is' basis and may lag behind the
register. Access may be withdrawn or restricted at any time.

  REFERRER http://www.nominet.org.uk

  REGISTRAR Nominet UK

SERVERS

  SERVER co.uk.whois-servers.net

  ARGS arwatch.co.uk

  PORT 43

  TYPE domain

DISCLAIMER
This WHOIS information is provided for free by Nominet UK the central registry
for .uk domain names. This information and the .uk WHOIS are:
Copyright Nominet UK 1996 - 2017.
You may not access the .uk WHOIS or use any data from it except as permitted
by the terms of use available in full at http://www.nominet.uk/whoisterms,
which includes restrictions on: (A) use of the data for advertising, or its
repackaging, recompilation, redistribution or reuse (B) obscuring, removing
or hiding any or all of this notice and (C) exceeding query rate or volume
limits. The data is provided on an 'as-is' basis and may lag behind the
register. Access may be withdrawn or restricted at any time.

  REGISTERED no

DOMAIN

  NAME arwatch.co.uk

NSERVER

  NS68.1AND1.CO.UK 217.160.81.173

  NS67.1AND1.CO.UK 217.160.80.173

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .